• No results found

University of Groningen Chronic limb-threatening ischemia Ipema, Jetty

N/A
N/A
Protected

Academic year: 2021

Share "University of Groningen Chronic limb-threatening ischemia Ipema, Jetty"

Copied!
9
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Hele tekst

(1)

University of Groningen

Chronic limb-threatening ischemia

Ipema, Jetty

DOI:

10.33612/diss.170945328

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date: 2021

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Ipema, J. (2021). Chronic limb-threatening ischemia: Optimizing endovascular and medical treatment. University of Groningen. https://doi.org/10.33612/diss.170945328

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

(2)

Chronic limb-threatening ischemia

Optimizing endovascular and

medical treatment

(3)

Chronic limb-threatening ischemia: optimizing endovascular and medical treatment

PhD thesis, University Medical Center Groningen, with a summary in Dutch Cover design: Remco Alexander Top

Printed by: Ipskamp Printing Copyright © J. Ipema 2021

All rights reserved. No part of this book may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, without prior permission of the publisher and copyright owner, or where appropriate, the publisher of the articles.

The author gratefully acknowledges financial support of this thesis by: Graduate School of Medical Sciences Universitair Medisch Centrum Groningen and Rijksuniversiteit Groningen, and Stichting Lijf en Leven.

(4)

Chronic limb-threatening ischemia:

optimizing endovascular and

medical treatment

PhD thesis

to obtain the degree of PhD at the

University of Groningen

on the authority of the

Rector Magnificus Prof. C. Wijmenga

and in accordance with

the decision by the College of Deans.

This thesis will be defended in public on

Monday 14 June 2021 at 16.15 hours

by

Jetty Ipema

born on 1 June 1991

in Glimmen

(5)

Supervisors

Prof. J.P.P.M. de Vries Dr. Ç. Ünlü

Assessment committee

Prof. J.A.M. Zeebregts Prof. W. Wisselink Prof. H.J.M. Verhagen

(6)
(7)

Chapter 1 General introduction

Endovascular treatment

Chapter 2 Drug-coated balloon angioplasty vs. standard percutaneous transluminal angioplasty in below- the-knee peripheral arterial disease: a systematic review and meta-analysis

Chapter 3 Outcomes of the paclitaxel-eluting Eluvia stent for long femoropopliteal lesions in Asian patients with predominantly chronic limb-threatening ischemia Chapter 4 Early and midterm experience with the Absorb

everolimus-eluting bioresorbable vascular scaffold in Asian patients with chronic limb-threatening ischemia: one-year clinical and imaging outcomes from the DISAPEAR registry

Chapter 5 A systematic review and meta-analysis of bioresorbable vascular scaffolds for below-the- knee arterial disease

Chapter 6 Midterm outcomes of an everolimus-eluting bioresorbable vascular scaffold in patients with below-the-knee arterial disease: a pooled analysis of individual patient data

Chapter 7 Repeatability, and intraobserver and interobserver agreement of two dimensional perfusion angiography in patients with chronic limb-threatening ischemia

Contents

9 23 49 67 85 111 129

(8)

Medical treatment

Chapter 8 Medical adjunctive therapy for patients with chronic limb-threatening ischemia: a systematic review

Chapter 9 Antiplatelet and anticoagulation therapy after revascularization for lower extremity artery disease: a national survey and literature overview Chapter 10 Short-term clinical outcomes of single versus

dual antiplatelet therapy after infrainguinal endovascular treatment for peripheral arterial disease

Chapter 11 Summary, general discussion and future perspectives

Nederlandse samenvatting, algemene discussie en toekomstvisie

Chapter 12 Graduation committee Co-authors and affiliations Dankwoord List of publications Curriculum vitae 151 219 255 275 290 308 309 311 313 315

(9)

Referenties

GERELATEERDE DOCUMENTEN

The following keywords were used: below the knee, infrapopliteal, tibial arteries, tibial artery, crural, peripheral arterial disease, peripheral artery disease, critical

This patency rate was better compared with hybrid drug coverage with the Eluvia stent and DCB or the combination of Eluvia and BMS or POBA, while the total lesion coverage group

In the AMS INSIGHT study (Bioabsorbable Metal Stent Investigation in Chronic Limb Ischemia Treatment), 117 CLTI patients (Rutherford category 4 or 5) with 149 lesions

The keywords used were bioabsorbable stent, bioabsorbable scaffold, bioresorbable scaffold, bioresorbable stent, biodegradable stent, biodegradable scaffold, peripheral

This pooled analysis showed that the Absorb BVS can be safely used for the treatment of patients with CLTI due to infrapopliteal artery disease with favorable rates of

This study investigated the reliability of 2DPA as a foot perfusion measurement tool in patients with CLTI and demonstrated excellent repeatability and intra- and

A meta-analysis of ten studies comparing bone marrow stem cell therapy with placebo in patients with CLTI showed no significant differences in major amputation, mortality and

Multivariate analysis of 12-month major adverse limb event (MALE) outcomes between patients receiving single antiplatelet therapy (SAPT) and patients receiving dual